Brentuximab vedotin combined with donor lymphocyte infusions for early relapse of Hodgkin lymphoma after allogeneic stem-cell transplantation induces tumor-specific immunity and sustained clinical remission.

Subjects

Subjects :

Antineoplastic Agents administration & dosage
Antineoplastic Agents adverse effects
Brentuximab Vedotin
CD4-Positive T-Lymphocytes immunology
Combined Modality Therapy
Drug Administration Schedule
Graft vs Host Disease etiology
HLA-A2 Antigen immunology
Hodgkin Disease drug therapy
Hodgkin Disease surgery
Humans
Immunoconjugates administration & dosage
Immunoconjugates adverse effects
NK Cell Lectin-Like Receptor Subfamily B immunology
Polyneuropathies chemically induced
Recurrence
Remission Induction
Shock, Septic etiology
T-Lymphocytes, Cytotoxic immunology
Th17 Cells immunology
Thrombocytopenia chemically induced
Transplantation, Homologous
Treatment Outcome
Antineoplastic Agents therapeutic use
Apoptosis immunology
Hematopoietic Stem Cell Transplantation adverse effects
Hodgkin Disease immunology
Hodgkin Disease therapy
Immunoconjugates therapeutic use
Immunotherapy, Adoptive methods
Ki-1 Antigen antagonists & inhibitors
Lymphocytes immunology
T-Lymphocytes immunology

Details

Language :

English

ISSN :

1527-7755

Volume :

31

Issue :

5

Database :

MEDLINE

Journal :

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Publication Type :

Academic Journal

Accession number :

23269992

Full Text :

https://doi.org/10.1200/JCO.2012.43.6832